Thank you, Seth and good afternoon everyone. For further information regarding our fiscal year 2020 financial results and disclosures, please refer to our earnings release that we filed at the close of market yesterday and our Form 10-K that we will file with the SEC later today. The company maintained a strong working capital position at December 31, 2020. As of December 31, 2020, we had $21.5 million of cash and cash equivalents compared to $18 million at December 31, 2019. We had working capital of $17.1 million at December 31, 2020, as compared to $18.1 million at December 31, 2019, with no debt financing. Total assets, was a $21.8 million and total liabilities were $4.6 million at December 31, 2020. Total cash use and operating activities increased by approximately $1.9 million for the fiscal year 2020 compared to fiscal year 2019, primarily due to an increase in G&A expenses relating to our arbitration matter, offset by a decrease in our R&D expenses as we no longer conduct our R&D activities in Enfission as we did in 2019 since we transitioned our R&D work to the U.S. National Labs in 2020. Cash used in investing activities decreased by approximately $3.6 million for the year ended December 31, 2020, compared to 2019, due to us terminating our equity contributions into the Enfission joint venture in 2019. Cash provided by financing activities increased by approximately $8.6 to $12.4 million for fiscal 2020 compared to $3.8 million for fiscal 2019. The increase was primarily due to an increase in the net proceeds from the issuance of our common stock, which resulted from the sale of approximately 3.3 million shares of common stock for net proceeds of $12.3 million for the year ended December 31, 2020. Before I hand the call over to Sherrie Holloway, our Accounting Manager, I would like to add that as a result of certain triggering events regarding our intangible asset, patent costs, that we recorded an impairment loss provision on the total carrying value of our patent costs. Total impairment loss and patent write-off was $1.2 million recorded in the fourth quarter of 2020. There was no patent impairment loss provision in 2019. Due to the COVID-19 pandemic, we took the necessary steps in fiscal year 2020 to reduce our corporate overhead expense, and we anticipate preserving our cash runway into calendar year 2022. As noted, we received the GAIN Voucher from the DOE today, and we will continue to strive to obtain additional DOE funding in the future, with the primary goal of furthering our fuel development in the most cost-efficient manner for our shareholders to support our future financing requirements with respect to our nuclear fuel development. I will now turn the call over to Sherrie Holloway, our Accounting Manager, who will go over our P&L financial information for fiscal 2020.